Theriva Biologics, Inc. 8-K

What Happened
Theriva Biologics, Inc. (TOVX) filed a Form 8-K on March 12, 2026 to disclose that it issued a press release containing financial information for the fiscal year ended December 31, 2025. The press release is attached to the 8-K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Filing date: March 12, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Subject: Financial information for the fiscal year ended December 31, 2025 was included in the press release.
• Exhibit: Press release is attached as Exhibit 99.1; the filing also includes the interactive XBRL cover page (Exhibit 104).
• Company: Theriva Biologics, Inc., a Nevada corporation (ticker: TOVX).

Why It Matters
This 8-K signals that Theriva has publicly released its full-year 2025 financial results and made them available to investors via a press release. Investors should review Exhibit 99.1 (the press release) and the company’s other SEC filings for the specific numbers (revenue, net income/loss, cash position, and any management commentary) because those figures can affect valuation, liquidity assessment, and near-term expectations for the stock.